AstraZeneca PLC (AZN)
76.98
-0.06
(-0.08%)
USD |
NASDAQ |
May 15, 16:00
77.04
+0.06
(+0.08%)
After-Hours: 20:00
AstraZeneca Price to Book Value: 6.374 for May 15, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 6.379 |
| May 13, 2024 | 6.411 |
| May 10, 2024 | 6.390 |
| May 09, 2024 | 6.426 |
| May 08, 2024 | 6.373 |
| May 07, 2024 | 6.319 |
| May 06, 2024 | 6.273 |
| May 03, 2024 | 6.322 |
| May 02, 2024 | 6.276 |
| May 01, 2024 | 6.327 |
| April 30, 2024 | 6.283 |
| April 29, 2024 | 6.250 |
| April 26, 2024 | 6.224 |
| April 25, 2024 | 6.212 |
| April 24, 2024 | 5.895 |
| April 23, 2024 | 5.866 |
| April 22, 2024 | 5.807 |
| April 19, 2024 | 5.676 |
| April 18, 2024 | 5.660 |
| April 17, 2024 | 5.674 |
| April 16, 2024 | 5.652 |
| April 15, 2024 | 5.691 |
| April 12, 2024 | 5.707 |
| April 11, 2024 | 5.750 |
| April 10, 2024 | 5.640 |
| Date | Value |
|---|---|
| April 09, 2024 | 5.664 |
| April 08, 2024 | 5.606 |
| April 05, 2024 | 5.585 |
| April 04, 2024 | 5.576 |
| April 03, 2024 | 5.532 |
| April 02, 2024 | 5.548 |
| April 01, 2024 | 5.568 |
| March 31, 2024 | |
| March 28, 2024 | 5.366 |
| March 27, 2024 | 5.407 |
| March 26, 2024 | 5.254 |
| March 25, 2024 | 5.217 |
| March 22, 2024 | 5.248 |
| March 21, 2024 | 5.243 |
| March 20, 2024 | 5.206 |
| March 19, 2024 | 5.217 |
| March 18, 2024 | 5.216 |
| March 15, 2024 | 5.252 |
| March 14, 2024 | 5.310 |
| March 13, 2024 | 5.353 |
| March 12, 2024 | 5.339 |
| March 11, 2024 | 5.36 |
| March 08, 2024 | 5.267 |
| March 07, 2024 | 5.243 |
| March 06, 2024 | 5.170 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
4.211
Minimum
Dec 10 2021
13.47
Maximum
May 13 2020
7.784
Average
6.405
Median
Jun 20 2023
Price to Book Value Benchmarks
| GSK PLC | 5.333 |
| Amgen Inc | 34.08 |
| Sanofi SA | 1.495 |
| Viking Therapeutics Inc | 9.213 |
| Fusion Pharmaceuticals Inc | 7.569 |
Price to Book Value Related Metrics
| PE Ratio | 37.83 |
| PS Ratio | 5.051 |
| PEG Ratio | 1.088 |
| Price to Free Cash Flow | 41.57 |
| Price | 76.98 |
| Earnings Yield | 2.64% |
| Market Cap | 238.67B |
| PEGY Ratio | 1.032 |
| Operating PE Ratio | 25.24 |
| Normalized PE Ratio | 34.62 |